Viking治疗 VKTX 深 沪
已收盘 12-12 16:00:00 美东时间
37.08
-0.130
-0.35%
华盛通- 最 高38.50
- 今 开37.06
- 成交量 246.36万股
- 最 低 36.51
- 昨 收 37.21
- 总市值 41.53亿
- 52周最高 43.55
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 18.92
- 委 比 -89.69%
- 总股本 1.12亿
- 历史最高 99.41
- 量 比 0.91
- 振 幅 5.35%
- 历史最低 0.88
- 每 手 1
- 风险率 5.64%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多What's Up With The Jump In Viking Therapeutics Stock?
Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher on Thursday. The clinical-stage biopharmaceutical company seems to be benefitting from the wider excitement in obesity treatment area and the recent positive momentum after major clinical trial developments.
12-05 03:57
3 Weight-Loss Drug Stocks To Consider For 2026
The global weight loss drug market, perhaps ironically, is growing like gangbus...
11-22 02:58
Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves
Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven asset allocation.
11-15 05:59
美股大行评级 | 富国银行上调AMD目标价升至345美元；花旗上调礼来目标价升至1500美元；巴克莱上调腾讯音乐目标价升至28美元
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从12美元升至15美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从106美元升至107美元
11-13 09:58
Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $107
Canaccord Genuity analyst Edward Nash maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and raises the price target from $106 to $107.
11-12 21:09
Jim Cramer Says 'Take A Pass' On This Tech Stock, Won't Go Near Oils
Zoom Communications is a good company, Cramer says. Still, he advises, "take a pass." Plus: Viking Therapeutics, Profrac and Altria.
11-05 21:33
美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
10-30 14:22
华尔街顶级分析师最新评级报告：联合健康遭下调
华尔街最受关注、且能影响市场走势的研究评级报告现已汇总于此。以下是由 The Fly 整理的今日投资者需重点关注的评级信息。 五大评级上调案例 思佳讯...
10-29 22:12
Eli Lilly readies billions of weight-loss pills ahead of U.S. approval
Eli Lilly (NYSE:LLY) has already manufactured billions of doses of its next-generation weight-loss pill, anticipating strong global demand ahead of a potential launch next year. “We’ve already made, a...
10-28 20:35
美股大行评级 | 升至45美元！英特尔获多家机构上调目标价；大摩上调拖拉机供应公司(TSCO)评级至"标配"，目标价升至60美元
今日重点评级关注：HC Wainwright & Co.：维持Alto Neuroscience"买入"评级，目标价从10美元升至50美元；RBC Capital：维持Precision Drilling"跑赢大市"评级，目标价从110美元升至117美元
10-27 09:45
